MIV Therapeutics Premieres Research into Advanced Polymer-free Drug Delivery Systems at Leading Biomedical Conference; MIVT Premieres Revolutionary Drug Eluting System Based on its Proprietary Hydroxyapatite Coating Technologies.

VANCOUVER, British Columbia -- MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, presented their latest achievements in research and development of a revolutionary polymer-free coatings and drug delivery systems for vascular stents and other implantable medical devices, at the 2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA.

At the conference, MIVT revealed to industry and scientific professionals for the first time the latest research findings into its newest, revolutionary polymer-free drug eluting technology. Most importantly, the preliminary evaluation of these potentially breakthrough coatings confirmed their exceptional suitability for drug delivery purposes and delivered extremely promising drug eluting characteristics.

MIVT is developing advanced drug-eluting coatings for stents and other devices based on the use of porous calcium phosphate, a non-polymer alternative drug-carrying vehicle designed to eliminate problems associated with current polymer-based coatings now in use. Under the Company's research program, micro-thin films of calcium phosphates were deposited on a layer of ultra-thin Hydroxyapatite (HAp) as a vehicle for drug delivery purposes for a variety of implantable medical devices. MIVT already completed developing ultra-thin non-porous HAp coatings that have demonstrated exceptional biocompatibility and safety.

"The presentation of our newest coating and drug eluting technologies at the Boston conference gave us an opportunity for MIVT to make a decisive testimony of our achievements and capabilities before the industry's leading scientists and professionals," said Alan Lindsay, Chairman and CEO of MIVT. "The superb biocompatibility and safety of our proprietary coatings, complemented with the extremely promising characteristics of our drug delivery solutions, are designed to directly target the weaknesses of present drug delivery technologies used in cardiovascular stents and other medical devices. We are very pleased with preliminary evaluation results of these breakthrough technologies, which have generated considerable interest and appreciation throughout our industry."

Arc Rajtar, MIVT's Chief Technology Officer, assisted by Dr. Quanzu Yang, Ph.D., of the UBC's Department of Materials Engineering, delivered a comprehensive presentation of MIVT proprietary coating and drug delivery technologies titled, "Hydroxyapatite Coatings for Coronary Stents." The presentation highlighted the achievements of the MIVT and UBC research teams. The Hydroxyapatite-based technologies presented at the conference included sol-gel, electro-chemical and electrophoretic methods of deposition, which resulted in ultra-thin, calcium-phosphate bio-ceramic films. Long-term evaluation of MIVT's ultra-thin films used as a surface modification for metallic implants confirmed their exceptional biocompatibility and excellent safety during animal trials completed recently at the Methodist Hospital in Houston, TX.

MIVT's new line of ultra-thin and drug-eluting coatings for cardiovascular stents and other medical devices utilize material called Hydroxyapatite (HAp). MIVT is developing its coating systems to target the estimated $6 billion worldwide stent market. MIVT's coating solutions are also targeting the broader range of implantable medical devices, estimated to have the potential to grow to $100 billion or more in coming years.

"The Materials & Processes Conference gave us a unique audience to premiere our ultra-thin coating technologies for the professional community," said Mr. Rajtar. "The high-resolution electronic microscopy pictures of our polymer-free drug eluting coatings and the research results we presented were very well-received by our scientific peers and key industry representatives."

MIVT's R&D teams are continuing to accelerate the pace of work on the Company's breakthrough solutions. As a result of encouraging research findings, this portion of the Company's development program is approximately 6 months ahead of schedule, Mr. Rajtar added.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings and drug delivery systems for cardiovascular stents and for application on broad range of implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated superior biocompatibility and excellent safety pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coatings are designed to suit broad range of implantable medical devices which are expected to benefit from a highly customizable drug release profile not offered by competitive solutions. MIVT's Collaborative Research Agreement (CRA) with the University of British Columbia is supported with research and development grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.